Evaluation of Cognitive Functions in People Living with HIV Before and After COVID-19 Infection

Overview

Journal Viruses

Publisher MDPI

Date 2025 Jan 25

PMID 39861924

Authors

Dimtrios Basoulis

Elpida Mastrogianni

Irene Eliadi

Nikolaos Platakis

Dimitris Platis

Mina Psichogiou

Affiliations

Soon will be listed here.

Abstract

Background: Cognitive function decline is a problem in aging people living with HIV (PLWHIV). COVID-19 infection is associated with neuropsychiatric manifestations that may persist. The aim of our study was to evaluate cognitive function in PLWHIV before and after COVID-19 infection.

Methods: This was a prospective observational study conducted at "Laiko" General Hospital from July 2019 to July 2024. The Montreal Cognitive Assessment (MOCA) scale was used to evaluate cognitive functions.

Results: 116 virally suppressed PLWHIV participated (mean age: 47.6 years, 91.4% male); 60 underwent repeated evaluation after the pandemic at a median interval of 3.1 years. The median MOCA score was 24 (22-26), with 35.3% scoring within normal limits. A negative correlation was observed between MOCA scores and age (ρ = -0.283, = 0.002), but not with a CD4 count at diagnosis (ρ = 0.169, = 0.071) or initial HIV RNA load (ρ = 0.02, = 0.984). In the subgroup with repeated testing, MOCA was correlated with the CD4 count (ρ = 0.238, = 0.069 in the first and ρ = 0.319, = 0.014 second test). An improvement in performance was observed (median score increase from 24 to 25, = 0.02).

Conclusions: MOCA can detect early changes in cognitive function in PLWHIV. Further studies are required to determine the role of COVID-19 over time.

References

Poptsi E, Moraitou D, Eleftheriou M, Kounti-Zafeiropoulou F, Papasozomenou C, Agogiatou C . Normative Data for the Montreal Cognitive Assessment in Greek Older Adults With Subjective Cognitive Decline, Mild Cognitive Impairment and Dementia. J Geriatr Psychiatry Neurol. 2019; 32(5):265-274. DOI: 10.1177/0891988719853046. View

Gupta A, Goyal A, Rajan R, Vishnu V, Kalaivani M, Tandon N . Validity of Montreal Cognitive Assessment to Detect Cognitive Impairment in Individuals with Type 2 Diabetes. Diabetes Ther. 2024; 15(5):1155-1168. PMC: 11043253. DOI: 10.1007/s13300-024-01549-y. View

Thompson M, Horberg M, Agwu A, Colasanti J, Jain M, Short W . Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2020; 73(11):e3572-e3605. DOI: 10.1093/cid/ciaa1391. View

Munoz-Moreno J, Perez-Alvarez N, Munoz-Murillo A, Prats A, Garolera M, Jurado M . Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables. PLoS One. 2014; 9(9):e107625. PMC: 4169550. DOI: 10.1371/journal.pone.0107625. View

Nightingale S, Ances B, Cinque P, Dravid A, Dreyer A, Gisslen M . Cognitive impairment in people living with HIV: consensus recommendations for a new approach. Nat Rev Neurol. 2023; 19(7):424-433. DOI: 10.1038/s41582-023-00813-2. View

Lim X, Chew P, Lim G, Low Y, Lim J, Ong H . Montreal cognitive assessment as a screening instrument for cognitive impairment in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus. 2022; 31(14):1759-1769. DOI: 10.1177/09612033221132237. View

Garabet R, Dampier W, Tillman S, Malone K, Szep Z, Althoff A . CD4 nadir and neurocognitive trajectories in people living with HIV. J Neurovirol. 2024; 30(4):423-433. PMC: 11512832. DOI: 10.1007/s13365-024-01217-8. View

Agarwal R, Aujla R, Gupta A, Kumar M . Determining the Neurocognitive Status and the Functional Ability of Patients to Screen for HIV-Associated Neurocognitive Disorder (HAND). Dement Neurocogn Disord. 2020; 19(1):19-27. PMC: 7105717. DOI: 10.12779/dnd.2020.19.1.19. View

Vassallo M, Fabre R, Durant J, Lebrun-Frenay C, Joly H, Ticchioni M . A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. J Neurovirol. 2016; 23(2):216-225. DOI: 10.1007/s13365-016-0490-z. View

10.

Yan C, Cooley S, Ances B . Veterans Aging Cohort Study Index 2.0 Shows Improved Discrimination of Neurocognitive Impairment and Frailty in People with HIV. J Acquir Immune Defic Syndr. 2024; 97(1):63-67. PMC: 11611228. DOI: 10.1097/qai.0000000000003458. View

11.

Trunfio M, Vuaran E, Vai D, Quarta C, Di Stefano A, Imperiale D . Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study. AIDS Behav. 2024; 28(11):3643-3654. DOI: 10.1007/s10461-024-04440-w. View

12.

Basoulis D, Mastrogianni E, Voutsinas P, Psichogiou M . HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment. Viruses. 2023; 15(2). PMC: 9962407. DOI: 10.3390/v15020577. View

13.

Schild A, Scharfenberg D, Regorius A, Klein K, Kirchner L, Yasemin G . Six-month follow-up of multidomain cognitive impairment in non-hospitalized individuals with post-COVID-19 syndrome. Eur Arch Psychiatry Clin Neurosci. 2024; 274(8):1945-1957. PMC: 11579205. DOI: 10.1007/s00406-024-01863-3. View

14.

Valcour V, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A . HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients. PLoS One. 2013; 8(7):e70164. PMC: 3729685. DOI: 10.1371/journal.pone.0070164. View

15.

Janssen M, Bosch M, Koopmans P, Kessels R . Validity of the Montreal Cognitive Assessment and the HIV Dementia Scale in the assessment of cognitive impairment in HIV-1 infected patients. J Neurovirol. 2015; 21(4):383-90. PMC: 4510920. DOI: 10.1007/s13365-015-0324-4. View

16.

Basoulis D, Pantazis N, Paraskevis D, Iliopoulos P, Papadopoulou M, Akinosoglou K . HIV RNA/DNA Levels at Diagnosis Can Predict Immune Reconstitution: A Longitudinal Analysis. Microorganisms. 2023; 11(6). PMC: 10300907. DOI: 10.3390/microorganisms11061510. View

17.

Peluso M, Spinelli M, Deveau T, Forman C, Munter S, Mathur S . Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. AIDS. 2022; 36(12):F7-F16. PMC: 9444925. DOI: 10.1097/QAD.0000000000003338. View

18.

Zigmond A, SNAITH R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x. View

19.

Wilcox D, Rudmann E, Ye E, Noori A, Magdamo C, Jain A . Cognitive concerns are a risk factor for mortality in people with HIV and coronavirus disease 2019. AIDS. 2023; 37(10):1565-1571. PMC: 10355333. DOI: 10.1097/QAD.0000000000003595. View

20.

Rosca E, Albarqouni L, Simu M . Montreal Cognitive Assessment (MoCA) for HIV-Associated Neurocognitive Disorders. Neuropsychol Rev. 2019; 29(3):313-327. DOI: 10.1007/s11065-019-09412-9. View